{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:54:34Z","timestamp":1776905674337,"version":"3.51.2"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Herein we report the confirmation of N-debenzisothiazole-lurasidone as a lurasidone degradation product associated with postmortem toxicology casework. Confirmation was realized by unambiguous synthesis and comparison of its LC\u2013MS\/MS properties to the lurasidone degradation product in postmortem blood using liquid chromatography quadrupole-time-of-flight mass spectrometry (LC\u2013QTOF\/MS). The mechanism of formation of this degradant in blood is proposed to be primarily enzymatic, given it has only been previously presumptively reported in one in vitro stability study following oxidative stress conditions. It has not been reported in other in vivo pharmacokinetic and in vitro stability studies assessing lurasidone stability toward acid, alkali, oxidation, photolysis, and heat. The detection of N-debenzisothiazole-lurasidone in postmortem casework indicates that, where possible, it should be included in toxicology screening methods targeting psychoactive compounds. Until such time that a commercially available reference standard of N-debenzisothiazole-lurasidone is available, the comprehensive accurate mass and mass spectral data of N-debenzisothiazole-lurasidone that are now available enable its inclusion as a \u201csuspect target\u201d in high-resolution MS screening methods.<\/jats:p>","DOI":"10.1093\/jat\/bkaf097","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T11:53:05Z","timestamp":1761133985000},"source":"Crossref","is-referenced-by-count":0,"title":["Identification of\n                    <i>N<\/i>\n                    -debenzisothiazole-lurasidone as an enzymatic degradation product of lurasidone"],"prefix":"10.1093","volume":"50","author":[{"given":"Kyle","family":"Farrell","sequence":"first","affiliation":[{"name":"Forensic Science SA, Forensic Science Centre , Adelaide, South Australia, 5000,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tristan","family":"Fraser","sequence":"additional","affiliation":[{"name":"Forensic Science SA, Forensic Science Centre , Adelaide, South Australia, 5000,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Butzbach","sequence":"additional","affiliation":[{"name":"Forensic Science SA, Forensic Science Centre , Adelaide, South Australia, 5000,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1959-2873","authenticated-orcid":false,"given":"Jared","family":"Castle","sequence":"additional","affiliation":[{"name":"Victorian Institute of Forensic Medicine , Southbank, Melbourne, 3006,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7666-4039","authenticated-orcid":false,"given":"Kenneth Paul","family":"Kirkbride","sequence":"additional","affiliation":[{"name":"College of Science and Engineering, Flinders University , Bedford Park, Adelaide, South Australia, 5042,","place":["Australia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"2026042220282565600_bkaf097-B1","author":"Sunovion","year":"2013"},{"key":"2026042220282565600_bkaf097-B2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord"},{"key":"2026042220282565600_bkaf097-B3","first-page":"180","article-title":"The International College of Neuro-Psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017), Part 3: the clinical guidelines","volume":"20","author":"Fountoulakis","year":"2017","journal-title":"Int J Neuropsychopharmacol"},{"key":"2026042220282565600_bkaf097-B4","author":"European Medicines Agency","year":"2020"},{"key":"2026042220282565600_bkaf097-B5","author":"Therapeutic Goods Administration","year":"2014"},{"key":"2026042220282565600_bkaf097-B6","volume-title":"Disposition of Toxic Drugs and Chemical in Man","author":"Baselt","year":"2014","edition":"10th edn"},{"key":"2026042220282565600_bkaf097-B7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3892\/br.2024.1779","article-title":"Efficacy and safety of lurasidone for schizophrenia: A systematic review and meta\u2011analysis of eight short\u2011term, randomized, double\u2011blind, placebo\u2011controlled clinical trials","volume":"20","author":"Gao","year":"2024","journal-title":"Biomed Rep"},{"key":"2026042220282565600_bkaf097-B8","doi-asserted-by":"crossref","DOI":"10.1136\/bmjment-2024-301165","article-title":"Efficacy and acceptability of lurasidone for bipolar depression: a systematic review and dose\u2013response meta-analysis","volume":"27","author":"Lin","year":"2024","journal-title":"BMJ Ment Health"},{"key":"2026042220282565600_bkaf097-B9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1055\/a-2331-2300","article-title":"Discontinuation rate of lurasidone and quetiapine extended release in bipolar depression","volume":"57","author":"Kishi","year":"2024","journal-title":"Pharmacopsychiatry"},{"key":"2026042220282565600_bkaf097-B10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/0269881115620460","article-title":"A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia","volume":"30","author":"Tandon","year":"2016","journal-title":"J Psychopharmacol"},{"key":"2026042220282565600_bkaf097-B11","first-page":"136194","article-title":"Glossopharyngeal dystonia secondary to a lurasidone-fluoxetine CYP-3A4 interaction","volume":"2013","author":"Paul","year":"2013","journal-title":"Case Rep Psychiatry"},{"key":"2026042220282565600_bkaf097-B12","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3851\/IMP3059","article-title":"Case report A case of a probable drug interaction between lurasidone and atazanavir-based antiretroviral therapy","volume":"21","author":"Naccarato","year":"2016","journal-title":"Antivir Ther"},{"key":"2026042220282565600_bkaf097-B13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1080\/15563650.2017.1388385","article-title":"Asenapine, iloperidone and lurasidone exposures in young children reported to U.S. poison centers","volume":"56","author":"Stassinos","year":"2018","journal-title":"Clin Toxicol (Phila)"},{"key":"2026042220282565600_bkaf097-B14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1177\/8755122514533305","article-title":"Lurasidone ingestions reported to texas poison centers","volume":"30","author":"Forrester","year":"2014","journal-title":"J Pharm Technol"},{"key":"2026042220282565600_bkaf097-B15","first-page":"708","article-title":"Retrospective evaluation of lurasidone ingestions reported to the national poison data system [abstract]","volume":"51","author":"Van Nest","year":"2013","journal-title":"Clin Toxicol"},{"key":"2026042220282565600_bkaf097-B16","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1080\/15563650.2020.1737102","article-title":"Characterization of intentional lurasidone ingestions using the United States National Poison Data System","volume":"58","author":"Weiss","year":"2020","journal-title":"Clin Toxicol"},{"key":"2026042220282565600_bkaf097-B17","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1097\/JCP.0000000000000224","article-title":"Acute lurasidone overdose","volume":"34","author":"Molnar","year":"2014","journal-title":"J Clin Psychopharmacol"},{"key":"2026042220282565600_bkaf097-B18","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1097\/JCP.0000000000000774","article-title":"Lurasidone-associated neuroleptic malignant syndrome","volume":"37","author":"Lee","year":"2017","journal-title":"J Clin Psychopharmacol"},{"key":"2026042220282565600_bkaf097-B19","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/JCP.0000000000001781","article-title":"Neuroleptic malignant syndrome associated with lurasidone: a case report","volume":"43","author":"P\u00e0mpols-P\u00e9rez","year":"2023","journal-title":"J Clin Psychopharmacol"},{"key":"2026042220282565600_bkaf097-B20","doi-asserted-by":"crossref","first-page":"891757","DOI":"10.3389\/fpsyt.2022.891757","article-title":"Psychotic symptoms and malignant neuroleptic syndrome in williams syndrome: a case report","volume":"13","author":"Karpov","year":"2022","journal-title":"Front Psychiatry"},{"key":"2026042220282565600_bkaf097-B21","first-page":"152","article-title":"Neutropenia in a schizophrenia patient following combined lurasidone and \u00adpaliperidone therapy: a case report","volume":"32","author":"Mielczarek","year":"2023","journal-title":"Postep Psychiatr Neurol"},{"key":"2026042220282565600_bkaf097-B22","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/9781119062585.ch9","volume-title":"Forensic Microbiology","author":"Castle","year":"2017"},{"key":"2026042220282565600_bkaf097-B23","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1002\/dta.3239","article-title":"Investigations into the stability of 17 psychoactive drugs in a \u201csimulated postmortem blood\u201d model","volume":"14","author":"Castle","year":"2022","journal-title":"Drug Test Anal"},{"key":"2026042220282565600_bkaf097-B24","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/dta.3441","article-title":"Microbial degradation products of lurasidone and their significance in postmortem toxicology","volume":"15","author":"Castle","year":"2023","journal-title":"Drug Test Anal"},{"key":"2026042220282565600_bkaf097-B25","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1556-4029.2012.02280.x","article-title":"Bacterial degradation of risperidone and paliperidone in decomposing blood","volume":"58","author":"Butzbach","year":"2013","journal-title":"J Forensic Sci"},{"key":"2026042220282565600_bkaf097-B26","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/dta.1503","article-title":"An unusual case of risperidone instability in a fatality presenting an analytical and interpretative challenge","volume":"5","author":"Taylor","year":"2013","journal-title":"Drug Test Anal"},{"key":"2026042220282565600_bkaf097-B27","doi-asserted-by":"crossref","first-page":"115834","DOI":"10.1016\/j.jpba.2023.115834","article-title":"Separation and characterization of related substances of Lurasidone hydrochloride by LC-QTOF-MS techniques","volume":"238","author":"Siddig","year":"2024","journal-title":"J Pharm Biomed Anal"},{"key":"2026042220282565600_bkaf097-B28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpba.2014.11.035","article-title":"Structural characterization of alkaline and oxidative stressed degradation products of lurasidone using LC\/ESI\/QTOF\/MS\/MS","volume":"105","author":"Kumar Talluri","year":"2015","journal-title":"J Pharm Biomed Anal"},{"key":"2026042220282565600_bkaf097-B29","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1080\/00397911.2015.1074695","article-title":"Enantioselective synthesis of ((1 R, 2 R)-cyclohexane-1, 2-diyl) bis (methylene) dimethanesulfonate, a lurasidone hydrochloride intermediate","volume":"45","author":"Ganesh","year":"2015","journal-title":"Synth Commun"},{"key":"2026042220282565600_bkaf097-B30","first-page":"0256939","author":"Ae","year":"2014"},{"key":"2026042220282565600_bkaf097-B31","author":"Mishra","year":"2017"},{"key":"2026042220282565600_bkaf097-B32","first-page":"62","article-title":"Stability indicating HPTLC method development and validation for lurasidone","volume":"8","author":"Patel","year":"2017","journal-title":"Pharma Science Monitor"},{"key":"2026042220282565600_bkaf097-B33","doi-asserted-by":"crossref","first-page":"e4871","DOI":"10.1002\/jms.4871","article-title":"Structural elucidation of two novel degradants of lurasidone and their formation mechanisms under free radical-mediated oxidative and photolytic conditions via liquid chromatography-photodiode array\/ultraviolet-tandem mass spectrometry and one-dimensional\/two-dimensional nuclear \u00admagnetic resonance spectroscopy","volume":"57","author":"Wang","year":"2022","journal-title":"J Mass Spectrom"},{"key":"2026042220282565600_bkaf097-B34","author":"Silvermann","year":"2018"},{"key":"2026042220282565600_bkaf097-B35","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3390\/pharmaceutics15010232","article-title":"Improving lurasidone hydrochloride\u2019s solubility and stability by higher-order complex formation with hydroxypropyl-\u03b2-cyclodextrin","volume":"15","author":"Gamboa-Arancibia","year":"2023","journal-title":"Pharmaceutics"},{"key":"2026042220282565600_bkaf097-B36","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1093\/jat\/bkx108","article-title":"A validated method for the screening of 320 forensically significant compounds in blood by LC\/QTOF, with simultaneous quantification of selected compounds","volume":"42","author":"Partridge","year":"2018","journal-title":"J Anal Toxicol"}],"container-title":["Journal of Analytical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jat\/advance-article-pdf\/doi\/10.1093\/jat\/bkaf097\/64925107\/bkaf097.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jat\/article-pdf\/50\/2\/bkaf097\/64925107\/bkaf097.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jat\/article-pdf\/50\/2\/bkaf097\/64925107\/bkaf097.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:28:37Z","timestamp":1776904117000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jat\/article\/doi\/10.1093\/jat\/bkaf097\/8300991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4,22]]}},"URL":"https:\/\/doi.org\/10.1093\/jat\/bkaf097","relation":{},"ISSN":["0146-4760","1945-2403"],"issn-type":[{"value":"0146-4760","type":"print"},{"value":"1945-2403","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,10,24]]},"article-number":"bkaf097"}}